



* Department of Pediatrics, Division of Neonatology
Department of Obstetrics and Gynecology, Sacred Heart Hospital, University of Florida, Pensacola, Florida
| ABSTRACT |
|---|
|
|
|---|
Study Design/Methods. Pregnant women 25 to 33 weeks gestation, who remained undelivered 1 week after their first course of antenatal corticosteroids (two 12-mg doses of betamethasone) were randomized to weekly courses of corticosteroids versus weekly placebo until delivery or 34 weeks gestation. FRC was measured with the nitrogen washout technique and respiratory compliance with the single breath occlusion technique within 48 hours of life.
Results. Thirty-seven infants (mean gestational age at delivery
32.5 weeks) were studied. Maternal and infant demographics were similar. There was no significant difference in FRC (28.5 vs 27.5 mL/kg) or respiratory compliance between the infants who received a single remote course of antenatal corticosteroids and those who received weekly courses of corticosteroids until delivery. There was no significant difference in admission head circumference or birth weights between the groups.
Conclusions. Our results demonstrate that weekly repetitive courses of AS do not significantly increase FRC or respiratory compliance in preterm infants when compared with a single remote course of steroids given at a mean gestational age of 29 weeks.
Key Words: functional residual capacity antenatal corticosteroids respiratory compliance respiratory distress syndrome preterm infants
Abbreviations: AS, antenatal steroids RDS, respiratory distress syndrome NIH, National Institutes of Health FRC, functional residual capacity Crs, passive respiratory compliance ACTH, adrenocorticotrophic hormone
| INTRODUCTION |
|---|
|
|
|---|
Pulmonary function testing has been used to quantify the newborn infants physiologic response to therapeutic interventions.3,4 We have used pulmonary function testing as an objective way of quantifying the effect of different permutations of AS on functional residual capacity (FRC, or lung volume at the end of expiration) and passive respiratory compliance (Crs), 5,6 and have correlated these measurements with clinical outcomes. There are no randomized data on the effect of repetitive dosing of AS on pulmonary function in preterm infants.
The objective of our study was to quantify and compare the effect of weekly courses of AS versus a single remote course of AS, ie, an initial course of AS followed by weekly courses of placebo, on lung volume (FRC) and Crs in preterm infants. Based on our previous data, we hypothesized that these 2 groups of preterm infants would have comparable FRC measurements.
| METHODS |
|---|
|
|
|---|
Study Design/Methods
A randomized, double-blinded study design was used, with group assignment done through the pharmacy using a randomization table. The study medication was prepared by the pharmacy, and the investigators and clinical care providers were unaware of the treatment allocation. Pulmonary function including FRC and Crs were measured within 48 hours of age. Comparison of the FRC measurements between the 2 groups of infants was our primary endpoint. Clinical outcome measures between the groups were monitored, and a subset of patients had an adrenocorticotrophic hormone (ACTH) stimulation test performed. Infants were studied supine while quietly asleep. Infants who required surfactant had to be studied before its administration (rescue therapy).
Measurements
FRC and respiratory mechanics were measured with a computerized infant pulmonary function cart (SensorMedics 2600, SensorMedics, Inc, Yorba Linda, CA). FRC was measured with the nitrogen washout method810 and respiratory mechanics with the single-breath occlusion technique.11,12 Both measurements can be performed in intubated and extubated infants, as previously reported.5,6
For the nitrogen washout technique,5,6,810 calibration was done with 2 known volumes, and a calibration line was constructed for the system at the specific flow rate. The infant was switched in at end expiration from his/her baseline fraction of inspired oxygen to 100% oxygen at the flow rate used for calibration. The calibration curve was then used to correlate the nitrogen washed out to the infants FRC. The system corrected for dead space present and corrected the FRC to body temperature, pressure, and water-saturated conditions. Total FRC was related to body weight. Acceptance criteria included the following: 1) infant supine and quietly asleep; 2) test initiated at end expiration; 3) no evidence of leak on tracing of the washout; 4) consistent tracings; and 5) a coefficient of variation <10%.13
Passive respiratory mechanics were measured with the single-breath occlusion technique.5,6,11,12 The airway was occluded at end inspiration until an airway pressure plateau was observed and the Hering Breuer reflex invoked. From the passive flow-volume curve, respiratory system compliance and resistance were calculated. Acceptance criteria included the following: 1) stable end expiratory baseline; 2) plateau pressure lasting >100 msec; 3) plateau pressure varying by < ± 0.125 cm H2O; 4) acceptable flow-volume curve by visual inspection, with linear data segment identified; and 5) at least 10 breaths accepted with a coefficient of variation of <20%.13
Clinical outcome parameters including admission head circumference, surfactant administration, days on oxygen, and mechanical ventilation were monitored. A subset of patients had an ACTH stimulation test14 performed on day 5 of life using the chemiluminescence method (Access Cortisol, Beckman Instruments, Inc, Fullerton, CA). For this test, Cortrosyn (Organen Inc, West Orange, NJ) (ACTH) 36 µg/kg was given intravenously, and cortisol levels were drawn before and 30 minutes after Cortrosyn administration.
Statistical Analysis
We have reported a 50% increase in FRC in preterm infants treated with a single course of AS when compared with untreated infants.5 For this study, we hypothesized that the FRC of the single course remote group would be no >10% smaller than the FRC measured in the repetitive AS group. If the 2 treatment groups are equivalent in terms of FRC changes, we estimated we would need to study
25 patients in each group to reject the null hypothesis with an
of 0.05 and a power of 80%. An interim analysis was performed after the enrollment of
40 patients. At that time there was no trend toward a difference in FRC between the groups, and because of increasing data of possible adverse effects of repetitive AS therapy we believed it was ethically appropriate to stop enrollment of patients. Our current sample size allows us to say that the average FRC in the single course remote group is no >12% smaller than the average FRC in the repetitive group with an
of 0.05 and a power of 80%.
An intention-to-treat analysis was performed. Differences in FRC and respiratory mechanics were evaluated using the Student t test for independent samples (2-tailed). Student t test or Mann-Whitney U test were used to compare continuous variables, and categorical variables were analyzed with Pearson
2 or Fisher exact test as appropriate (SPSS for Windows, version 7.5, SPSS, Chicago, IL). Statistical significance was set at P < .05 for all tests.
| RESULTS |
|---|
|
|
|---|
|
14 days after dosing with AS. There was no significant difference in FRC or Crs between these infants.
|
|
|
| DISCUSSION |
|---|
|
|
|---|
Studies of pulmonary mechanics after repetitive AS therapy in preterm lamb models have had different results. One study16 using the maternal route of administration demonstrated incremental increases in lung volume and compliance with additional doses of betamethasone, whereas a separate study20 using fetal administration showed no significant improvement in lung function after retreatment. The difference in the conclusions of these studies may be attributable to differences in the route of administration of AS, gestational age at the initiation of treatment, or interval between doses required to achieve the cumulative effect. Jobe et al21 examined the effect of fetal and maternal administration of repetitive antenatal corticosteroids given at 7-day intervals in preterm lambs. In this study, both modes of therapy significantly increased lung function, but the maternal route of administration was the more potent, implicating the probable induction of a maturational agent through the placenta.
Similar to animals studies, we have reported a 50% increase in both FRC and Crs in 20 preterm infants (mean gestational age: 28.8 weeks) who received a single course of AS when compared with 20 matched infants who did not receive AS therapy.5 The FRC values of the single course remote group and of the weekly repetitive group in our present study are very consistent with our previously published FRC values in the group treated with a single course of AS.5 Our present randomized trial does not demonstrate incremental increases in FRC with repetitive dosing of AS. The remote single course group continued to have a comparable FRC to the repetitive group regardless of dosing to delivery interval. These results seem to support the premise of a long-lasting structural effect of AS on lung volume (FRC). Unlike our previous nonrandomized study,6 which demonstrated the repetitively treated infants to have a significantly higher Crs compared with the single course group, we demonstrated only a trend for a difference in Crs between the 2 groups of infants in our present study. The difference in the Crs measurements between the 2 studies may have been attributable to the following: differences in study design (nonrandomized vs randomized); different total AS dosages given to the repetitive groups; and different mean time intervals from dosing of AS until delivery between the 2 studys single course remote groups.
The consistent measurement of FRC is important in that it reflects the growth and development of the lung, can be used to quantify treatment responses, to predict the disease course, and is an important reference value for other measurements of pulmonary mechanics. Increases in FRC after AS therapy can be secondary to structural changes in the lungs, increased surfactant production, and/or secondary to increased distension of patent alveoli, decreased atelectasis, and decreased pulmonary edema.10,22 Our findings of an increased FRC after a single course of AS therapy are consistent with the improved clinical outcomes in treated preterm infants including decreased RDS.1,2 Of interest, the infants in the present study without RDS had a significantly higher FRC than those who had RDS.
A recently published randomized study23 evaluating the effect of repetitive courses of AS versus a single course of AS demonstrated no differences in composite morbidity (including severe RDS and bronchopulmonary dysplasia), birth weight, or admission head circumference between the 2 groups of infants. There was a reduced risk of severe RDS in infants <28 weeks gestation in the repetitive group. Previous retrospective studies have had varying results, but have raised concern regarding repetitive AS therapy and possible fetal growth retardation. French et al18 reported no decrease in RDS after multiple courses of antenatal steroids, but did report a decrease in birth weight and head circumference with increasing courses of AS. Banks et al17 found that infants exposed to >2 courses of AS had a lower birth weight, those exposed to >3 courses had an increased risk of death, and found no relationship between the incidence of RDS and the number of courses of steroids. Although not the primary endpoints of our study, we found no significant difference in the clinical outcome measures between the 2 groups of infants.
Our study was randomized and double-blinded, but it still had some limitations. We did not see a difference in clinical outcome measures between the 2 groups of infants, but our sample size did not have the power to address these issues as it was based on changes in FRC as the primary endpoint. Only 14% of our study population delivered at <28 weeks gestation, thus more information is needed in these very low birth weight infants. Our study involved a relatively small number of patients so we cannot rule out a ß error completely, but it is unlikely that there would be a significant difference in FRC between the 2 groups because no trend was detected. Our current sample size allows us to say that the FRC in the single course remote group is no >12% smaller than the FRC in the repetitive group with an
of 0.05 and a power of 80%. Several maternal factors and events surrounding delivery can stimulate the secretion of endogenous steroids and impact the subsequent measurement of lung function. With randomization, there was no significant difference between the 2 groups in terms of important maternal or infant risk factors. In addition, all pulmonary function tests were performed at a median age of 24 hours in both groups, or before surfactant therapy if clinically indicated.
| CONCLUSION |
|---|
|
|
|---|
| ACKNOWLEDGMENTS |
|---|
We thank the neonatologists, obstetricians, intensive care nurses, and respiratory therapists at Sacred Heart Hospital who helped facilitate this study. We also thank Dr Manuel Durand and Dr James Padbury for critical review of the manuscript.
| FOOTNOTES |
|---|
Reprint requests to (C.M.) Pediatrics Department (CDRC-P), Oregon Health and Science University, 707 SW Gaines Rd, Portland, OR 97201-2998. E-mail: mcevoyc{at}ohsu.edu
This study was presented, in part, at the Society for Pediatric Research Annual Meeting, Baltimore, MD, May 1, 2001.
| REFERENCES |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
C. McEvoy, D. Schilling, P. Spitale, D. Peters, J. O'Malley, and M. Durand Decreased Respiratory Compliance in Infants Less Than or Equal to 32 Weeks' Gestation, Delivered More Than 7 Days After Antenatal Steroid Therapy Pediatrics, May 1, 2008; 121(5): e1032 - e1038. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. M. Peltoniemi, M. A. Kari, O. Tammela, L. Lehtonen, R. Marttila, E. Halmesmaki, P. Jouppila, M. Hallman, and for the Repeat Antenatal Betamethasone Study Group Randomized Trial of a Single Repeat Dose of Prenatal Betamethasone Treatment in Imminent Preterm Birth Pediatrics, February 1, 2007; 119(2): 290 - 298. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. B. Bracken, E. W. Triche, K. Belanger, A. Saftlas, W. S. Beckett, and B. P. Leaderer Asthma Symptoms, Severity, and Drug Therapy: A Prospective Study of Effects on 2205 Pregnancies Obstet. Gynecol., October 1, 2003; 102(4): 739 - 752. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||